
Sign up to save your podcasts
Or


The paper examines the cost-effectiveness of schedules of bone-modifying agents in patients with breast cancer and skeletal metastases and supports the 3-month administration of the generic zoledronic acid in terms of cost and efficacy.
Read the accompanying article on JCO.org.
By American Society of Clinical Oncology (ASCO)3.8
3939 ratings
The paper examines the cost-effectiveness of schedules of bone-modifying agents in patients with breast cancer and skeletal metastases and supports the 3-month administration of the generic zoledronic acid in terms of cost and efficacy.
Read the accompanying article on JCO.org.

14,364 Listeners

137 Listeners

320 Listeners

498 Listeners

58 Listeners

112,758 Listeners

44 Listeners

32 Listeners

195 Listeners

90 Listeners

364 Listeners

253 Listeners

189 Listeners

41 Listeners

613 Listeners